| HOME >> MEDICINE >> TECHNOLOGY |
Taxotere Sales by Indication (2009-2017)130
S-1 Sales (2009-2017) 135
Xeloda Sales by Company (2009-2017). 143
Xeloda Sales by Indication (2009-2017). 143
Probability of Launch. 157
List of Charts
Gastric Cancer Sales by Therapy (2010)2
Market Share by Product (2010)4
Market Share of Gastric Cancer Therapies (2010)5
Market Share of Gastric Cancer Therapies (2017).5
Market Share by Product (2017)6
Major Players in Gastric Cancer by Market Share (2010).8
Major Players in Gastric Cancer by Market Share (2017).9
Competitor Ratio Analysis Scores. 11
HER2 Signalling Pathway22
Herceptin Sales (2009-2017)30
Afinitor Mode of Action 31
Afinitor Sales (2009-2017).37
Avastin Mode of Action38
Avastin Sales by Company (2009-2017)49
Avastin Sales by Indication, 2010.52
Avastin Sales by Indication, 2017.52
Erbitux Sales (2009-2017)60
Ramucirumab Sales (2014-2017)65
Tykerb/Tyverb Total Sales (2009-2017)72
Tykerb Sales by Indication, 201773
AUY922 Mode of Action Within a Cancer Cell.83
Nexavar's Dual Mode of Action89
Schematic of EGFr Inhibition in Tumourigenesis.111
TAX 317 Survival K_M Curves - Docetaxel 75mg/m2 vs Best Supportive Care 123
TAX 320 Survival K_M Curves - Docetaxel 75mg/m2 vs Vinorelbine or Ifosfamide Control. 124
Taxotere Sales (2009-2017) 129
Taxotere Sales by Indication (2010).130
Taxotere Sales by Indication (2017) 131
S-1 Sales (2009-2017). 134
Xeloda Sales (2009-2017) 142
Xeloda Sales by Indication (2010) 143
Xeloda Sales by Indication (2017)144
To order this report:
: Gastric Cancer Drug Discoveries: what the future holds
'/>"/>| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |